Navigation Links
Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines
Date:9/19/2012

uding: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.

As shared solutions in clinical research and other areas are developed, TransCelerate will involve industry alliances including Clinical Data Interchange Standards Consortium (CDISC), Critical-Path Institute (C-Path), Clinical Trials Transformation Initiative (CTTI), Innovative Medicines Initiative (IMI), regulatory bodies including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Contract Research Organizations (CROs).

Janet Woodcock, MD, director of FDA's Center for Drug Evaluation and Research, said, "We applaud the companies in TransCelerate BioPharma for joining forces to address a series of longstanding challenges in new drug development. This collaborative approach in the pre-competitive arena, utilizing the collective experience and resources of 10 leading drug companies and others to follow, has the promise to lead to new paradigms and cost savings in drug development, all of which would strengthen the industry and its ability to develop innovative and much-needed therapies for patients."

"These leading pharmaceutical companies are in a position to significantly influence changes in the way that clinical trials are done, so that better answers about the benefits and risks of drugs and other therapies are provided in a more efficient manner," said Robert Califf, MD, Co-Chair of CTTI and Director of the Duke Translational Medicine Institute.  "This initiative is complementary to efforts of CTTI, and we look forward to working with TransCelerate BioPharma to improve the conduct of clinical trials."

TransCelerate BioPharma evolved from relationships fostered vi
'/>"/>

SOURCE TransCelerate BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... CHICAGO Professional networking has traditionally been a face-to-face ... in person. , ,Since the technology boom, the ... innovations such as e-mail list servs and online social ... person to start building relationships. , ,The Midwest ...
... missing angels, those investors who provide the seed money that ... lots of early start-ups who are looking for those angels. ... investors willing to take even a small risk on a ... few investors, who had some interesting points to share with ...
... , ,Eau Claire, Wis. - Small Tree ... has released Mac OS X drivers for Intel's new ... of the Apple Xserve G5's built-in Ethernet card, ... targeted at high-performance media and file servers. They are ...
Cached Biology Technology:Using Technology to Professionally Network in the Midwest 2Using Technology to Professionally Network in the Midwest 3Using Technology to Professionally Network in the Midwest 4Angels step up 2Angels step up 3Small Tree provides Apple drivers for Intel's new 10-gigabit Ethernet cards 2
(Date:10/14/2014)... 14, 2014)—It,s been millions of years since T. ... led by Ohio University scientists is breathing life back ... through dinosaur snouts. The research has important implications for ... but to enhance the sense of smell and cool ... said Ohio University doctoral student Jason Bourke, lead author ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
(Date:10/14/2014)... doses of fish oil supplements, rich in omega-3 fatty acids, ... heartbeat in which the heart can beat as fast as ... led by the Montreal Heart Institute were published in the ... October 7th. , For the trial, 337 patients with atrial ... 4 grams of fish oil a day or to placebo ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... HOUSTON -- (April 22, 2013) -- Individual freedom and ... investigation of the genetic circuitry of bacteria suggests that ... strike a balance between selflessness and selfishness. In ... researchers from Rice University,s Center for Theoretical Biological Physics ...
... 22, 2013 Three new studies involving tree nuts ... pistachios and walnuts) were presented this week at the ... was associated with a better nutrient profile and diet ... syndrome; and a decrease in several cardiovascular risk factors ...
... pleased to announce a new license arrangement that ... characteristics of CSIRO,s Reversible Addition-Fragmentation chain Transfer polymerisation ... development capabilities for the biotech industry., Mirus Bio ... the agreement would allow the company to broaden ...
Cached Biology News:Genetic circuit allows both individual freedom, collective good 2Genetic circuit allows both individual freedom, collective good 3Genetic circuit allows both individual freedom, collective good 4New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass. 2New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass. 3
... The SearchLight® IR Mouse Cytokine Array ... assay) for the quantitative measurement of 12 ... plasma and culture supernatants. Each well of ... that capture specific cytokines in standards and ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
Biology Products: